Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
356.4 USD | +0.56% | +0.92% | +19.03% |
Apr. 26 | Well, it isn't as bad as feared... | |
Apr. 26 | The Cigna Group Enters Revolving Credit Facility | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.52 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.03% | 101B | B- | ||
-7.11% | 456B | B- | ||
+13.24% | 125B | A- | ||
-0.51% | 39.69B | B- | ||
-33.78% | 36.86B | A- | ||
-4.82% | 20.05B | B- | ||
-12.48% | 3.08B | C+ | ||
-41.00% | 993M | B- | ||
-29.20% | 337M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CI Stock
- Ratings Cigna